Loading
Fulvestrant / Breast Cancer / Capivasertib · Phase 3 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an active Phase 3 registry record for a multi-center study of capivasertib plus fulvestrant in Chinese patients with HR+/HER2- advanced breast cancer resistant to 1–2 lines of prior endocrine therapy. No results have been posted in the registry; the trial is currently recruiting or recently closed to accrual, and efficacy and safety data are not yet available for evaluation.
Phase 3, Interventional, Non Randomized, Parallel, Open label, Treatment purpose. Breast Cancer; age from 18 Years. Intervention: Cohort 1; Cohort 2. n = 293. 76 sites: China.
This is an active Phase 3 registry record for a multi-center study of capivasertib plus fulvestrant in Chinese patients with HR+/HER2- advanced breast cancer resistant to 1–2 lines of prior endocrine therapy. No results have been posted in the registry; the trial is currently recruiting or recently closed to accrual, and efficacy and safety data are not yet available for evaluation.
This is a registry record only; no results have been posted and no efficacy or safety data are available.
The source did not state who this applies to in practice.
This is a clinical trial registry record describing an active Phase 3 study with no results yet posted; the trial is ongoing and no efficacy or safety data are available for analysis.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06635447). This is a study registration, not published results. Lead sponsor: AstraZeneca. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 293 participants (ACTUAL). Conditions: Breast Cancer. Interventions: DRUG: Capivasertib; DRUG: Fulvestrant. Primary outcome measures: Time to first subsequent treatment (TFST) of PIK3CA/AKT1/PTEN-altered population in Cohort 1 , From the first dose of study intervention to the earlier of start date of the first subsequent therapy after discontinuation of study intervention, or death in PIK3CA/AKT1/PTEN-altered population in Cohort 1, up to approximately 2 years. Brief summary: This is a multi-center, two-cohorts, phase IIIb study of Capivasertib+Fulvestrant in HR+/HER2-ABC who had disease recurrence/progression following 1-2L endocrine therapy. The Primary objective is to assess the efficacy of capi+ful by assessment of TFST (Time to first subsequent treatment) of PIK3CA/AKT1/PTEN-altered subgroup in cohort1.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.